title: Takayasu's arteritis progression on anti-TNF biologics: a case series.
abstract: Takayasu's arteritis (TA) is a rare granulomatous vasculitic disease that affects the aorta and its major branches. Recent studies have suggested that anti-TNFα biological therapies are highly effective in treating TA refractory to conventional immunosuppressive therapy. We describe two patients with TA: one with progressive TA despite management with two different anti-TNFα agents, infliximab and adalimumab, and another who developed TA while treated with infliximab for the management of pre-existing Crohn's disease. From our observations, we believe that a multicentered randomized study should be designed to assess the extent of resistance to these agents when different therapeutic doses are employed for managing TA.
authors.affiliation: Division of Rheumatology, Department of Medicine, 562 HMRC University of Alberta, T6G 2S2, Edmonton, Alberta, Canada.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Osman
authors.forename: Stephen
authors.initials: S
authors.lastname: Aaron
authors.forename: Michelle
authors.initials: M
authors.lastname: Noga
authors.forename: Elaine
authors.initials: E
authors.lastname: Yacyshyn
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008279:Magnetic Resonance Imaging / Q000379:methods; D012074:Remission Induction; D013625:Takayasu Arteritis / Q000628:therapy*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab